Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Therapy with the oral antidiabetic agent troglitazone (Rezulin) has been associated with cases of severe hepatotoxicity and drug-induced liver failure, which led to the recent withdrawal of the product from the U.S. market. While the mechanism of this toxicity remains unknown, it is possible that chemically reactive metabolites of the drug play a causative role. In an effort to address this possibility, this study was undertaken to determine whether troglitazone undergoes metabolism in human liver microsomal preparations to electrophilic intermediates. Following incubation of troglitazone with human liver microsomes and with cDNA-expressed cytochrome P450 isoforms in the presence of glutathione (GSH), a total of five GSH conjugates (M1-M5) were detected and identified tentatively by LC-MS/MS analysis. In two cases (M1 and M5), the structures of the adducts were confirmed by NMR spectroscopy and/or by comparison with an authentic standard prepared by synthesis. The formation of GSH conjugates M1-M5 revealed the operation of two distinct metabolic activation pathways for troglitazone, one of which involves oxidation of the substituted chromane ring system to a reactive o-quinone methide derivative, while the second involves a novel oxidative cleavage of the thiazolidinedione (TZD) ring, potentially generating highly electrophilic alpha-ketoisocyanate and sulfenic acid intermediates. When troglitazone was administered orally to a rat, samples of bile were found to contain GSH conjugates which reflected the operation of these same metabolic pathways in vivo. The finding that metabolism of the TZD ring of troglitazone was catalyzed selectively by P450 3A enzymes is significant in light of the recent report that troglitazone is an inducer of this isoform in human hepatocytes. The implications of these results are discussed in the context of the potential for troglitazone to covalently modify hepatic proteins and to cause oxidative stress through redox cycling processes, either of which may play a role in drug-induced liver injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mechanistic studies subsequently identified bioactivation by CYP3A4 and CYP2C8 to reactive quinone-like metabolites and ring-opened sulfenic acid intermediates that covalently bind cellular macromolecules and trigger mitochondrial injury, neither of which was reliably flagged by standard preclinical hepatotoxicity assays [75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Fialuridine (Section 7.1) and troglitazone (Section 7.4) are intrinsic toxicodynamic failures, driven by human-relevant mitochondrial injury and reactive-metabolite formation, respectively.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Troglitazone, the first marketed thiazolidinedione, was withdrawn after reports of severe idiosyncratic hepatotoxicity, including fulminant liver failure and transplantation.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76]”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Fourth, idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
Citations
Cites
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00008 · Cited by 230
Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y., Kurumada, T., Hasegawa, K., & Horikoshi, H. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00122a022 · Cited by 221
Kohlroser, J., Mathai, J., Reichheld, J., Banner, B. F., & Bonkovsky, H. L. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01707.x · Cited by 209
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Kassahun, K., Hu, P. L., Grillo, M. P., Davis, M. R., Jin, L., & Baillie, T. A. (1994) · Chemico-Biological Interactions · doi:10.1016/0009-2797(94)90014-0 · Cited by 74
Self-citationOhe, T., Mashino, T., & Hirobe, M. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1185 · Cited by 64
Davis, M. R., Kassahun, K., Jochheim, C. M., Brandt, K. M., & Baillie, T. A. (1993) · Chemical Research in Toxicology · doi:10.1021/tx00033a020 · Cited by 44
Self-citation
Research works printed but not linked: 16
- Henry R. R., 1997, Thiazolidinones. Curr. Ther. Diabetes 26, 553−573
- Hu J., 1999, J. Org. Chem., 64
- Hart T. W., 1985, Tetrahedron Lett., 26
- Baillie T. A., 1993, Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319−325
- Kassahun K., 1997, Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: Identification of Phase I metabolites and glutathione conjugates. Chem. Res. Toxicol. 10, 1228−1233
- Borel A. G., 1993, Identification of carbomoylated thiol conjugates as metabolites of the antineoplastic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, in rats and humans. Drug Metab. Dispos. 21, 889−901
- Kawai K., 1997, Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneim.-Forsch. 47, 356−368
- Loi C. M., 1997, J. Clin. Pharmacol., 37
- Ohe T., 1997, Substituent elimination from p-substituted phenols by cytochrome P450. ipso-Substitution by the oxygen atom of the active species. Drug Metab. Dispos. 25, 116−122
- Ohe T., 2000, Novel metabolic pathway of estrone and 17β-estradiol catalyzed by cytochrome P-450. Drug Metab. Dispos. 28, 110−112
- Yamazaki H., 1999, Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 27, 1260−1266
- He K., 1999, Proceedings of the 9th North American ISSX Meeting, #207
- Polsker G. L., 1999, Troglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 57, 409−438
- Ramachandran V., 1999, Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. 27, 1194−1199
- Mansuy D., 1991, J. Am. Chem. Soc., 113
- Abbreviations TZD, thiazolidinedione
Cited by
Items 101–200 of 316
Jalving, M., Koornstra, J. J., de Jong, S., de Vries, E. G. E., & Kleibeuker, J. H. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02335.x · Cited by 54
Brink, A., Fontaine, F., Marschmann, M., Steinhuber, B., Cece, E. N., Zamora, I., & Pähler, A. (2014) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.7062 · Cited by 50
Bae, M., Rhee, H. M., & Song, B. J. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(02)00468-x · Cited by 56
Dufrasne, F., Gelbcke, M., Nève, J., Robert Kiss, A., & Kraus, J. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796957301 · Cited by 49
Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis
Fromenty, B. (2019) · Liver Research · doi:10.1016/j.livres.2019.06.001 · Cited by 52
Drug-Induced Idiosyncratic Hepatotoxicity: Prevention Strategy Developed after the Troglitazone Case
Ikeda, T. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rv-090 · Cited by 48
Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity
Saha, S., New, L. S., Ho, H. K., Chui, W. K., & Chan, E. C. Y. (2009) · Toxicology Letters · doi:10.1016/j.toxlet.2009.10.014 · Cited by 48
Metabolic Activation of Benzodiazepines by CYP3A4
Mizuno, K., Katoh, M., Okumura, H., Nakagawa, N., Negishi, T., Hashizume, T., Nakajima, M., & Yokoi, T. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024521 · Cited by 51
Madsen, K., Grönberg, G., Skonberg, C., Jurva, U., Hansen, S. H., & Olsen, J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx8002214 · Cited by 47
Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury
Kakuni, M., Morita, M., Matsuo, K., Katoh, Y., Nakajima, M., Tateno, C., & Yokoi, T. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.08.001 · Cited by 46
Idiosyncratic Drug Hepatotoxicity Revisited: New Insights from Mechanistic Toxicology
Boelsterli, U. A. (2003) · Toxicology Mechanisms and Methods · doi:10.1080/15376510309824 · Cited by 44
“2002), and reactiveα-ketoisocyanate and sulfenic acid intermediates from the thiazolidinedione ring bioactivation and scission (Kassahun et al. 2001; Tettey et al. 2001).”
BackgroundInfluentialDetecting reactive drug metabolites for reducing the potential for drug toxicity
Grillo, M. P. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1048222 · Cited by 43
“Other successful examples of the use of CNL 129 Da scanning for successful GSHadduct detection include in vitro liver microsome studies with troglitazone [53] and in vivo rat bile collection studies with disulfiram [54] (Supplemental Figure 2).”
MethodIdiosyncratic reactions and metabolism of sulfur-containing drugs
Zuniga, F. I., Loi, D., Ling, K. H. J., & Tang‐Liu, D. D. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.668528 · Cited by 48
“Scission of either the chromane or TDZ ring systems are culpable for RM formation [61] which may bind cellular macromolecules.”
BackgroundPulmonary Toxicity and Metabolic Activation of Dauricine in CD-1 Mice
Jin, H., Dai, J., Chen, X., Liu, J., Zhong, D., Gu, Y., & Zheng, J. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162297 · Cited by 43
“, 2007), troglitazone (Kassahun et al., 2001), tamoxifen (Fan et al.”
Models of Idiosyncratic Drug-Induced Liver Injury
Yokoi, T., & Oda, S. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-015007 · Cited by 38
Baughman, T. M., Graham, R., Wells‐Knecht, K. J., Silver, I. S., Tyler, L. O., Wells-Knecht, M. C., & Zhao, Z. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002683 · Cited by 42
“Evidence suggests that a potential cause of hepatotoxicity by troglitazone might be the formation of a reactive metabolite that could bind to cellular protein or DNA (Kassahun et al., 2001; Smith, 2003; Tolman and Chandramouli, 2003).”
BackgroundMechanism-Based Inactivation of Cytochrome P450 Enzymes: Computational Insights
Mirzaei, M. S., Ivanov, M. V., Taherpour, A. A., & Mirzaei, S. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00483 · Cited by 41
Inoue, K., Shibata, Y., Takahashi, H., Ohe, T., Chiba, M., & Ishii, Y. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.245 · Cited by 40
Biotransformations Leading to Toxic Metabolites
Macherey, A., & Dansette, P. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374194-3.00033-0 · Cited by 50
Mechanistic studies on the drug metabolism and toxicity originating from cytochromes P450
Jaladanki, C. K., Gahlawat, A., Rathod, G. K., Sandhu, H., Jahan, K., & Bharatam, P. V. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1765792 · Cited by 41
“It was reported that during metabolism of Troglitazone, quinone and quinone methide get generated, but only quinone methide is responsible for toxicity.”
BackgroundInfluentialStudies in Vitamin E: Biochemistry and Molecular Biology of Tocopherol Quinones
Cornwell, D. G., & Ma, J. (2007) · Vitamins and hormones · doi:10.1016/s0083-6729(07)76005-3 · Cited by 43
Selection of new chemical entities with decreased potential for adverse drug reactions
Park, K. B., Dalton-Brown, E., Hirst, C. M., & Williams, D. P. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.08.025 · Cited by 39
Identification of novel metabolites of pioglitazone in rat and dog
Shen, Z., Reed, J. R., Creighton, M. D., Liu, D. Q., Tang, Y., Hora, D. F., Feeney, W. P., Szewczyk, J. W., Bakhtiar, R., Franklin, R. B., et al. (2003) · Xenobiotica · doi:10.1080/0049825031000085951 · Cited by 39
“The mechanism of the thiazolidinedione ring scission may involve a novel biotransformation pathway (Kassahun et al. 2001), although the precise details of the underlying mechanism remain to be established.”
BackgroundHosomi, H., Akai, S., Minami, K., Yoshikawa, Y., Fukami, T., Nakajima, M., & Yokoi, T. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.11.020 · Cited by 39
Toxic Metabolite Formation from Troglitazone (TGZ): New Insights from a DFT Study
Dixit, V. A., & Bharatam, P. V. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200110h · Cited by 39
Saha, S., Chan, D. S. Z., Lee, C. Y., Wong, W., New, L. S., Chui, W. K., Yap, C. W., Chan, E. C. Y., & Ho, H. K. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.021 · Cited by 38
Non-cytochrome P450-mediated bioactivation and its toxicological relevance
Gan, J., Ma, S., & Zhang, D. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1225756 · Cited by 40
“CYP-mediated oxidative metabolism forms reactive metabolites (Gan et al., 2008; He et al., 2004; Kassahun et al., 2001; Tettey et al., 2001), and current understanding of troglitazone induced liver toxicity involves multiple mechanisms in addition to oxidative bioactivation including formation of…”
BackgroundQuantitative Chemical Proteomic Profiling of thein VivoTargets of Reactive Drug Metabolites
Whitby, L. R., Obach, R. S., Simon, G. M., Hayward, M. M., & Cravatt, B. F. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00346 · Cited by 40
The toxicogenomics of nuclear receptor agonists
Ulrich, R. G. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00080-2 · Cited by 38
Structural Alerts for Toxicity
Blagg, J. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc128 · Cited by 39
Bioactivation of herbal constituents: simple alerts in the complex system
Fang, Z., Zhang, Y., Wang, X.-L., Cao, Y., Huo, H., & Yang, L. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.586335 · Cited by 37
“5 Herbal components undergoing bioactivation to form quinone methide Many drugs undergo bioactivation to generate reactive quinone methide intermediates, such as tamoxifen [69], troglitazone [70] and trimethoprim [71].”
BackgroundAli, K., Mishra, P., Kumar, A., Reddy, D. N., Chowdhury, S., & Panda, G. (2022) · Chemical Communications · doi:10.1039/d2cc00838f · Cited by 36
Yamazaki, H., Kuribayashi, S., Inoue, T., Tateno, C., Nishikura, Y., Oofusa, K., Harada, D., Naito, S., Horie, T., & Ohta, S. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900323a · Cited by 36
Tang, S. Q., Lee, Y. Y. I., Packiaraj, D. S., Ho, H. K., & Chai, C. L. L. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00247 · Cited by 36
Expression pattern of human ATP ‐binding cassette transporters in skin
Takenaka, S., Itoh, T., & Fujiwara, R. (2013) · Pharmacology Research & Perspectives · doi:10.1002/prp2.5 · Cited by 35
“Not only UGTs but cytochrome P450s (CYPs), phase I drug-metabolizing enzymes, have also been reported to form reactive metabolites and be involved in drug-induced toxicities (Yamazaki et al. 1999; Kassahun et al. 2001).”
Mechanism-based inhibition of CYPs and RMs-induced hepatoxicity by rutaecarpine
Zhang, F., He, X., Zhai, Y., He, L.-N., Zhang, S.-C., Wang, L., Yang, A., & An, L. (2015) · Xenobiotica · doi:10.3109/00498254.2015.1038742 · Cited by 35
“…samples may provide indirect evidence of the presence of RMs. Metabolism studies performed in vivo are not always conducted at the early discovery stage, and thus, in vitro GSH trapping assays are utilized as an alternative means for assessing bioactivation potential (Kassahun et al., 2001).”
MethodThiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes
Singh, G., Kumar, R., Desna, D. S., Chaudhary, M., Kaur, C., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998254798231005095627 · Cited by 36
Schulz-Utermoehl, T., Sarda, S., Foster, J. R., Jacobsen, M. C., Kenna, J. G., Morikawa, Y., Salmu, J., Gross, G., & Wilson, I. D. (2011) · Xenobiotica · doi:10.3109/00498254.2011.640716 · Cited by 33
Okada, R., Maeda, K., Nishiyama, T., Aoyama, S., Tozuka, Z., Hiratsuka, A., Ikeda, T., Kusuhara, H., & Sugiyama, Y. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040469 · Cited by 33
“Full scan spectra were determined to detect five GSH conjugates of reactive metabolites of troglitazone as described previously (Kassahun et al., 2001).”
BackgroundMethodResultInfluentialToxicophores, reactive metabolites and drug safety: when is it a cause for concern?
Kalgutkar, A. S. S., Fate, G. D., Didiuk, M. T., & Bauman, J. N. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.4.515 · Cited by 33
Synthetic and semi-synthetic antioxidants in medicine and food industry: a review
Tauchen, J., Huml, L., Jurášek, M., Regenstein, J. M., & Özoğul, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1599816 · Cited by 39
Proteomic responses of HepG2 cell monolayers and 3D spheroids to selected hepatotoxins
Hurrell, T., Lilley, K. S., & Cromarty, D. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.10.030 · Cited by 32
Chemistry and Applications of Functionalized 2,4‐Thiazolidinediones
Ibrahim, A. M., Shoman, M. E., Mohamed, M. F. A., Hayallah, A. M., & Abuo‐Rahma, G. E. A. (2023) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202300184 · Cited by 32
Hagihara, K., Kazui, M., Kurihara, A., Iwabuchi, H., Ishikawa, M., Kobayashi, H., Tanaka, N., Okazaki, O., Farid, N. A., & Ikeda, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032086 · Cited by 32
“A sulfenic acid, which is a likely intermediate for the activation of prasugrel, reacts readily with a thiol compound, typically glutathione in vivo, to yield a disulfide metabolite (Decker et al., 1991; Kassahun et al., 2001; Reddy et al., 2005; Dansette et al., 2009).”
Hewitt, N. J., Lloyd, S., Hayden, M., Butler, R. K., Sakai, Y., Springer, R., Fackett, A., & Li, A. P. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00055-8 · Cited by 32
Hepatotoxicity of Cardiovascular and Antidiabetic Drugs
Marzio, D. H., & Navarro, V. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00029-7 · Cited by 55
Reactive Electrophiles and Metabolic Activation
Obach, R. S., & Kalgutkar, A. S. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00115-9 · Cited by 33
Bajrami, B., Zhao, L., Schenkman, J. B., & Rusling, J. F. (2009) · Analytical Chemistry · doi:10.1021/ac9015853 · Cited by 30
Yang, B., Liu, W., Chen, K., Wang, Z., & Wang, C. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058222 · Cited by 29
“Reactive metabolites may play a causative role (Kassahun et al., 2001).”
BackgroundGenetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Pachkoria, K., Lucena, M. I., Molokhia, M., Cueto-Galán, R., Carballo, A. S., Carvajal, A., & Andrade, R. J. (2007) · Current Drug Safety · doi:10.2174/157488607780598287 · Cited by 29
Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists
Fujimoto, T., Kunitomo, J., Tomata, Y., Nishiyama, K., Nakashima, M., Hirozane, M., Yoshikubo, S.-I., Hirai, K., & Marui, S. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.093 · Cited by 28
Coleman, M. D. (2020) · Wiley eBooks · doi:10.1002/9781119658016 · Cited by 48
Ware, B. R., McVay, M., Sunada, W. Y., & Khetani, S. R. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx059 · Cited by 27
“Reactive metabolites of troglitazone formed by CYP2C8 and CYP3A4 are implicated in hepatotoxicity (Kassahun et al., 2001; Usui et al., 2011).”
BackgroundBaillie, T. A., & Kassahun, K. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0667-6_5 · Cited by 27
Self-citationOECD (2014) · OECD series on testing and assessment · doi:10.1787/9789264085497-en · Cited by 28
Mitochondrial Dysfunction as a Mechanism for Pioglitazone-Induced Injury toward HepG2 Cell Line
Niknahad, H., Heidari, R., Alzuhairi, A. M., & Najibi, A. (2014) · Pharmaceutical Sciences · Cited by 37
Kalgutkar, A. S. S. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.09.003 · Cited by 29
Norman, B. H., Fisher, M. J., Schiffler, M. A., Kuklish, S. L., Hughes, N. E., Czeskis, B. A., Cassidy, K. C., Abraham, T. L., Alberts, J. J., & Luffer, D. R. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01806 · Cited by 26
Xu, J., Oda, S., & Yokoi, T. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.01.019 · Cited by 26
Kuribayashi, S., Goto, K., Naito, S., Kamataki, T., & Yamazaki, H. (2009) · Chemical Research in Toxicology · doi:10.1021/tx8003592 · Cited by 27
Mechanistic Studies on the Metabolic Scission of Thiazolidinedione Derivatives to Acyclic Thiols
Reddy, V., Karanam, B. V., Gruber, W. L., Wallace, M. A., Vincent, S. H., Franklin, R. B., & Baillie, T. A. (2005) · Chemical Research in Toxicology · doi:10.1021/tx0500373 · Cited by 26
Self-citationThe Importance of Tracking “Missing” Metabolites: How and Why?
Wang, S., Ballard, T. E., Christopher, L. J., Foti, R., Gu, C., Khojasteh, S. C., Liu, J., Ma, S., Ma, B., Obach, R. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01293 · Cited by 29
Troglitazone Inhibits Bile Acid Amidation: A Possible Risk Factor for Liver Injury
Ogimura, E., Nakagawa, T., Deguchi, J., Sekine, S., Ito, K., & Bando, K. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx091 · Cited by 28
Approaches for Minimizing Metabolic Activation of New Drug Candidates in Drug Discovery
Kumar, S., Mitra, K., Kassahun, K., & Baillie, T. A. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_19 · Cited by 24
Self-citationExploiting Endogenous Cellular Process to Generate Quinone Methides In Vivo
Cao, S., & Peng, X. (2014) · Current Organic Chemistry · doi:10.2174/138527281801140121123221 · Cited by 26
Taxak, N., Dixit, V. A., & Bharatam, P. V. (2012) · The Journal of Physical Chemistry A · doi:10.1021/jp308023g · Cited by 24
Taxak, N., Parmar, V. K., Patel, D. S., Kotasthane, A., & Bharatam, P. V. (2011) · The Journal of Physical Chemistry A · doi:10.1021/jp109935k · Cited by 24
Isoindolinone compounds active as Kv1.5 blockers identified using a multicomponent reaction approach
Kajanus, J., Jacobson, I., Åstrand, A., Olsson, R. I., Gran, U., Björe, A., Fjellström, O., Davidsson, Ö., Emtenäs, H., Dahlén, A., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.081 · Cited by 23
Genotoxicity in rats treated with the antidiabetic agent, rosiglitazone
Bedir, A., Aliyazıcıoğlu, Y., Kahraman, H., Yurdakul, Z., Uysal, M., Suvaci, D. E., Okuyucu, A., Hökelek, M., & Alvur, M. (2006) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20261 · Cited by 23
“The toxicity of the related TZD, troglitazone, has been attributed to the formation of a reactive quinone metabo- lite and to a quinone methide conjugate [Kassahun et al., 2001].”
BackgroundSegawa, M., Sekine, S., Sato, T., & Ito, K. (2018) · The Journal of Toxicological Sciences · doi:10.2131/jts.43.339 · Cited by 22
Boerma, J. S., Vermeulen, N. P. E., & Commandeur, J. N. M. (2011) · Chemical Research in Toxicology · doi:10.1021/tx2001515 · Cited by 24
Evaluation of mechanism of hepatotoxicity of leflunomide using albino wistar rats
Lodhi, L. (2013) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp2013.3517 · Cited by 22
“For example, five reactive intermediates have been identified for troglitazone in orally administered Sprague-Dawley rats which bound with GSH, and may lead to liver toxicity (Kassahun et al., 2001).”
BackgroundAssessment of genotoxicity in rats treated with the antidiabetic agent, pioglitazone
Bedir, A., Aliyazıcıoğlu, Y., Bilgici, B., Yurdakul, Z., Uysal, M., Suvaci, D. E., Okuyucu, A., Kahraman, H., Hökelek, M., & Alvur, M. (2008) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20365 · Cited by 22
“The toxicity of the related TZD, troglitazone, has been attrib- uted to the formation of a reactive quinone metabolite and to a quinone methide conjugate [Kassahun et al., 2001].”
Rendic, S. P., & Guengerich, F. P. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03710-9 · Cited by 21
Li, A. P. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140506114411 · Cited by 23
“L-glutathione conjugates) is routinely used as an early evaluation of potential drug toxicity, especially hepatotoxicity [59-65].”
BackgroundUchiyama, M., Fischer, T., Mueller, J., Oguchi, M., Yamamura, N., Koda, H., Iwabuchi, H., & Izumi, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031583 · Cited by 21
“…M3, M7, M8, and M11 were novel metabolites of pioglitazone, whereas M4, M5, M6, M9, M10, M12, and M13 were previously reported metabolites as M-VI, M-IV, M-V, M-VII, M-II, M-IX, and M-III, respectively (Krieter et al., 1994; Kiyota et al., 1997; Maeshiba et al., 1997; Shen et al., 2003) (Table 1).”
BackgroundResultInfluentialLee, D. W., Oh, W.-Y., Yi, S. H., Ku, B., Lee, M., Cho, Y. H., & Yang, M. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.07.711 · Cited by 21
Tahara, K., Nishikawa, T., Hattori, Y., Iijima, S., Kouno, Y., & Abe, Y. (2009) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2009.06.002 · Cited by 20
Liu, D. Q., Karanam, B. V., Doss, G. A., Sidler, R. R., Vincent, S. H., & Hop, C. E. C. A. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000059 · Cited by 20
“7 and not the sulfoxide-TZD, a possible intermediate leading to the TZD ring opening (Kassahun et al., 2001).”
BackgroundSelf-citationDixit, V. A., & Deshpande, S. (2016) · ChemistrySelect · doi:10.1002/slct.201601051 · Cited by 20
Molecular mechanisms of adverse drug reactions
Nelson, S. D. (2001) · Current Therapeutic Research · doi:10.1016/s0011-393x(01)80093-x · Cited by 23
Karanam, B. V., Hop, C. E. C. A., Liu, D. Q., Wallace, M., Dean, D. C., Satoh, H., Komuro, M., Awano, K., & Vincent, S. H. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000034 · Cited by 20
“TZD ring cleavage has been reported as a minor biotransformation pathway for troglitazone (Kassahun et al., 2001) and pioglitazone (Shen et al.”
BackgroundSelf-citation3-Methylene-2,4-chromandione in situ trapping: introducing molecular diversity on 4-hydroxycoumarin
Montagut-Romans, A., Boulven, M., Lemaire, M., & Popowycz, F. (2015) · RSC Advances · doi:10.1039/c5ra22440c · Cited by 19
Dansette, P. M., Levent, D., Hessani, A., Bertho, G., & Mansuy, D. (2013) · Chemical Research in Toxicology · doi:10.1021/tx400083b · Cited by 19
Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions
Liguori, M. J., & Waring, J. F. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.835 · Cited by 19
“With preference to CYP3A as a catalyst, TGZ possesses the ability in human liver microsomes to metabolise into an electrophilic intermediate with potential to covalently bind to cellular glutathione (GSH) and certain protein complexes [9,11].”
BackgroundLong-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty.
Bajpai, A., Sharma, J. N., Kabra, M., Gupta, A. K., & Menon, P. S. N. (2002) · PubMed · Cited by 19
Smith, D. A., Harrison, A. C., & Morgan, P. (2011) · Chemical Research in Toxicology · doi:10.1021/tx100408v · Cited by 18
Kennedy, E. L., Tchao, R., & Harvison, P. J. (2003) · Toxicology · doi:10.1016/s0300-483x(02)00692-3 · Cited by 18
Samuelsson, K., Pickup, K., Sarda, S., Foster, J. R., Randall, K., Abrahamsson, A., Jacobsen, M. C., Weidolf, L. O. G., & Wilson, I. D. (2014) · Xenobiotica · doi:10.3109/00498254.2013.879237 · Cited by 18
“Also, a number of reactive metabolites have been observed in human in vitro systems and it is unknown whether species differences in forming reactive metabolites could in part explain the human specific hepatotoxicity that was observed (Kassahun et al., 2001; Tettey et al., 2001).”
BackgroundBiotransformations Leading to Toxic Metabolites
Macherey, A., & Dansette, P. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00025-0 · Cited by 31
Morita, K., Mizuno, T., & Kusuhara, H. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00765 · Cited by 20
Ramírez-Molina, C., & Burton, L. (2009) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.4275 · Cited by 17
Green electrosynthesis of drug metabolites
Asra, R., & Jones, A. M. (2023) · Toxicology Research · doi:10.1093/toxres/tfad009 · Cited by 16
He, C., Mao, Y., & Wan, H. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2472076 · Cited by 17
Shi, X.-X., Wang, Z.-Z., Sun, X., Wang, Y., Liu, H., Wang, F., Hao, G., & Yang, G. (2023) · Green Chemistry · doi:10.1039/d2gc03973g · Cited by 19
In Vitro Metabolism of Oxymetazoline: Evidence for Bioactivation to a Reactive Metabolite
Mahajan, M. K., Uttamsingh, V., Daniels, J. S., Gan, L.-S. L., LeDuc, B. W., & Williams, D. A. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036004 · Cited by 16
“, 2005), and a reactive metabolite of troglitazone (Kassahun et al., 2001).”
BackgroundUetrecht, J. (2003) · Informa Healthcare eBooks · doi:10.1201/9781420028485.ch3 · Cited by 16
Troglitazone stimulates IGF-binding protein-1 by a PPARγ-independent mechanism
Hilding, A., Hall, K. E., Skogsberg, J., Ehrenborg, E., & LEWITT, M. S. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00403-0 · Cited by 15
Sequence-specific delivery of a quinone methide intermediate to the major groove of DNA
Zhou, Q., Pande, P., Johnson, A. E., & Rokita, S. E. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00151-1 · Cited by 15
Usui, T., Hashizume, T., Katsumata, T., Yokoi, T., & Komuro, S. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038661 · Cited by 14
Metadata
- Authors
- Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kassahun, Kelem
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-12-08
- Volume
- 14
- Issue
- 1
- Pages
- 62-70
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2068532562
- Cited by
- 311
- References
- 8
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 10 · 2020: 5 · 2019: 4 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 9 · 2014: 15 · 2013: 12 · 2012: 16
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Research in Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- troglitazone, drug metabolism, reactive metabolites, glutathione conjugates, CYP3A, hepatotoxicity, drug-induced liver injury, sulfenic acid, oxidative stress, redox cycling, covalent protein modification, human liver microsomes, bile
- MeSH terms
- Troglitazone, Animals, Bile, Biotransformation, Catalysis, Chromans, Chromatography, Liquid, Cytochrome P-450 Enzyme System, Glutathione, Humans, Hypoglycemic Agents, Isoenzymes, Ketoconazole, Kinetics, Microsomes, Liver, NADP, Mass Spectrometry, Steroid Hydroxylases, Thiazoles, Thiazolidinediones, Rats, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.